Limits of Peripheral Blood Mononuclear Cells for Gene Expression-Based Biomarkers in Juvenile Idiopathic Arthritis
Laiping Wong1, Kaiyu Jiang1, Yanmin Chen1
1Department of Pediatrics, University at Buffalo, Buffalo, NY, USA.
Insights
Investigating gene expression in Juvenile Idiopathic Arthritis (JIA) using peripheral blood mononuclear cells (PBMC) is challenging. Sample heterogeneity makes RNASeq on PBMC unsuitable for initial biomarker screening in JIA.
Area of Science:
- Pediatric rheumatology
- Genomic medicine
- Translational research
Background:
- Juvenile Idiopathic Arthritis (JIA) is a prevalent chronic childhood condition.
- Genomic technologies offer potential for JIA diagnosis and personalized medicine.
- Biomarker development is crucial for advancing JIA treatment strategies.
Purpose of the Study:
- To evaluate gene expression patterns in peripheral blood mononuclear cells (PBMC) for JIA biomarker discovery.
- To assess the suitability of RNA sequencing (RNASeq) on PBMC as a first-step biomarker screening method for JIA.
Main Methods:
- Exploration of gene expression patterns using RNA sequencing (RNASeq).
- Analysis of peripheral blood mononuclear cells (PBMC) from JIA patients.
- Assessment of sample heterogeneity as a factor in biomarker screening.
Main Results:
- Peripheral blood mononuclear cells (PBMC) exhibit significant sample heterogeneity.
- This heterogeneity complicates the interpretation of RNASeq data for JIA biomarker discovery.
- RNASeq on PBMC is not currently suitable as a primary screening method for JIA biomarkers.
Conclusions:
- Sample heterogeneity in PBMC poses a significant challenge for JIA biomarker development via RNASeq.
- Future biomarker discovery efforts in JIA may benefit from using more homogeneous cell populations.
- Refining methodologies for analyzing heterogeneous samples or utilizing alternative cell types is recommended for JIA research.
Abstract:
Juvenile Idiopathic Arthritis (JIA) is one of the most common chronic disease conditions affecting children in the USA. As with many rheumatic diseases, there is growing interest in using genomic technologies to develop biomarkers for either diagnosis or to guide treatment ("personalized medicine"). Here, we explore the use of gene expression patterns in peripheral blood mononuclear cells (PBMC) as a first step approach to developing such biomarkers. Although PBMC carry many theoretical advantages for translational research, we have found that sample heterogeneity makes RNASeq on PBMC unsuitable as a first-step method for screening biomarker candidates in JIA. RNASeq studies of homogeneous cell populations are more likely to be useful and informative.
More Related Videos
12:36Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
Published on: June 26, 2018
09:18Author Spotlight: Isolation and Culture of Primary Synovial Macrophages and Fibroblasts from Murine Arthritis Tissue
Published on: February 24, 2023